1. Globus Medical — the company was upgraded to “Neutral” by Zacks, according to a Sleek Money report. Zacks has a $21.20 price objective o the stock. At the same time, Canaccord Genuity reiterated their “buy” rating for Globus Medical with a price target at $28, up from the previous $24 target.
2. Zimmer — Zacks reiterated its neutral rating for Zimmer last week, with a $115 price target on Zimmer stock.
3. NuVasive — Canaccord Genuity analysts reiterated a “buy” rating on NuVasive shares with a price objective of $49, which would suggest a potential upside of 17.93 percent, according to a Sleek Monkey report. Barclays reaffirmed an “equal weight” rating in a Friday report with a $44 price objective on NuVasive stock, up from the previous $42.
4. Baxano Surgical — Baxano Surgical experienced a significant drop in short interest for October, according to a Ticker Report. The company’s short interest decreased 55.6 percent from the Sept. 30 total, with around 1.6 percent of the company’s stock being short sold.
5. Smith & Nephew — Jeffries Group restated a “hold” rating for Smith & Nephew shares last week with a target price of $15.94. Credit Suisse reiterated a “neutral” rating for the company as well with a price target of $15.06 on the stock. Morgan Stanley reiterated an equal weight rating on Smith & Nephew shares and lowered their price target to $15.65.
More articles on orthopedic devices:
Zimmer Biomet names new leaders
Mazor Robotics, K2M, Wright Medical Group & more—17 key notes
10 key concepts from Smith & Nephew’s financial report
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
